Giovanni de Simone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1709531/publications.pdf Version: 2024-02-01

		9784	2178
357	43,726	73	202
papers	citations	h-index	g-index
372	372	372	38758
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	2.2	6,826
2	Heart Disease and Stroke Statistics—2011 Update. Circulation, 2011, 123, e18-e209.	1.6	4,379
3	Heart Disease and Stroke Statistics—2010 Update. Circulation, 2010, 121, e46-e215.	1.6	4,053
4	Heart Disease and Stroke Statistics—2009 Update. Circulation, 2009, 119, 480-486.	1.6	2,334
5	2018 ESC/ESH Guidelines for the management of arterial hypertension. Journal of Hypertension, 2018, 36, 1953-2041.	0.5	2,129
6	Heart Disease and Stroke Statistics—2009 Update. Circulation, 2009, 119, e21-181.	1.6	2,039
7	Left ventricular mass and body size in normotensive children and adults: Assessment of allometric relations and impact of overweight. Journal of the American College of Cardiology, 1992, 20, 1251-1260.	2.8	1,573
8	Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. Journal of the American College of Cardiology, 1992, 19, 1550-1558.	2.8	1,413
9	Executive Summary: Heart Disease and Stroke Statistics—2010 Update. Circulation, 2010, 121, 948-954.	1.6	1,411
10	Effect of growth on variability of left ventricular mass: Assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. Journal of the American College of Cardiology, 1995, 25, 1056-1062.	2.8	830
11	2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension, 2018, 36, 2284-2309.	0.5	689
12	Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. Journal of the American College of Cardiology, 1994, 23, 1444-1451.	2.8	579
13	Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet, The, 2009, 374, 525-533.	13.7	391
14	Normal Limits in Relation to Age, Body Size and Gender of Two-Dimensional Echocardiographic Aortic Root Dimensions in Persons ≥15 Years of Age. American Journal of Cardiology, 2012, 110, 1189-1194.	1.6	303
15	Reliability of echocardiographic assessment of left ventricular structure and function. Journal of the American College of Cardiology, 1999, 34, 1625-1632.	2.8	297
16	Midwall Left Ventricular Mechanics. Circulation, 1996, 93, 259-265.	1.6	296
17	Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. American Journal of Hypertension, 2003, 16, 895-899.	2.0	263
18	2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood Pressure, 2018, 27, 314-340.	1.5	254

#	Article	IF	CITATIONS
19	Stroke Volume and Cardiac Output in Normotensive Children and Adults. Circulation, 1997, 95, 1837-1843.	1.6	253
20	Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. Journal of the American College of Cardiology, 2002, 39, 2005-2011.	2.8	250
21	Prognostic effect of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis. Heart, 2011, 97, 301-307.	2.9	243
22	Stroke Volume/Pulse Pressure Ratio and Cardiovascular Risk in Arterial Hypertension. Hypertension, 1999, 33, 800-805.	2.7	233
23	Left Ventricular Geometry in Children with Mild to Moderate Chronic Renal Insufficiency. Journal of the American Society of Nephrology: JASN, 2006, 17, 218-226.	6.1	231
24	Impact of Obesity on Cardiac Geometry and Function in a Population of Adolescents. Journal of the American College of Cardiology, 2006, 47, 2267-2273.	2.8	221
25	Normalization for body size and population-attributable risk of left ventricular hypertrophyThe Strong Heart Study. American Journal of Hypertension, 2005, 18, 191-196.	2.0	210
26	Effects of Once-Daily Angiotensin-Converting Enzyme Inhibition and Calcium Channel Blockade-Based Antihypertensive Treatment Regimens on Left Ventricular Hypertrophy and Diastolic Filling in Hypertension. Circulation, 2001, 104, 1248-1254.	1.6	204
27	Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. European Heart Journal, 2008, 29, 741-747.	2.2	203
28	Interaction Between Body Size and Cardiac Workload. Hypertension, 1998, 31, 1077-1082.	2.7	197
29	Evaluation of Concentric Left Ventricular Geometry in Humans. Hypertension, 2005, 45, 64-68.	2.7	182
30	Ethnic-Specific Normative Reference Values for Echocardiographic LAÂand LV Size, LV Mass, and Systolic Function. JACC: Cardiovascular Imaging, 2015, 8, 656-665.	5.3	182
31	Gender Differences in Left Ventricular Growth. Hypertension, 1995, 26, 979-983.	2.7	175
32	Cardiac Remodeling in Obesity. Circulation: Cardiovascular Imaging, 2013, 6, 142-152.	2.6	163
33	Relations of Left Ventricular Mass to Demographic and Hemodynamic Variables in American Indians. Circulation, 1997, 96, 1416-1423.	1.6	160
34	ESC Council on hypertension position document on the management of hypertensive emergencies. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 37-46.	3.0	155
35	Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. Journal of Hypertension, 2002, 20, 323-331.	0.5	146
36	Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study)**The views expressed here are those of the authors and do not necessarily reflect those of the Indian Health Service American Journal of Cardiology, 2004, 93, 40-44.	1.6	142

#	Article	IF	CITATIONS
37	Prognosis of Inappropriate Left Ventricular Mass in Hypertension. Hypertension, 2002, 40, 470-476.	2.7	139
38	Estimation of left ventricular chamber and stroke volume by limited M-mode echocardiography and validation by two-dimensional and doppler echocardiography. American Journal of Cardiology, 1996, 78, 801-807.	1.6	136
39	Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). European Journal of Echocardiography, 2008, 9, 809-815.	2.3	132
40	Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de EstimulaciÃ ³ n CardÃaca y ElectrofisiologÃa (SOLEACE). Europace, 2017, 19, 891-911.	1.7	124
41	Relation of Left Ventricular Diastolic Properties to Systolic Function in Arterial Hypertension. Circulation, 2000, 101, 152-157.	1.6	123
42	Improved cardiovascular diagnostic accuracy by pocket size imaging device in non-cardiologic outpatients: the NaUSiCa (Naples Ultrasound Stethoscope in Cardiology) study. Cardiovascular Ultrasound, 2010, 8, 51.	1.6	120
43	Risk Factors for Arterial Hypertension in Adults With Initial Optimal Blood Pressure. Hypertension, 2006, 47, 162-167.	2.7	119
44	Prognostic Impact of Metabolic Syndrome by Different Definitions in a Population With High Prevalence of Obesity and Diabetes. Diabetes Care, 2007, 30, 1851-1856.	8.6	118
45	Correlates of global area strain in native hypertensive patients: a three-dimensional speckle-tracking echocardiography study. European Heart Journal Cardiovascular Imaging, 2012, 13, 730-738.	1.2	118
46	2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. European Heart Journal Cardiovascular Imaging, 2017, 18, 930-936.	1.2	118
47	Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. Journal of Hypertension, 2010, 28, 353-360.	0.5	115
48	Relation of various degrees of body mass index in patients with systemic hypertension to left ventricular mass, cardiac output, and peripheral resistance (The Hypertension Genetic Epidemiology) Tj ETQq0 0	0 ng&T /O	ve rlæe k 10 Tf
49	Link of Nonhemodynamic Factors to Hemodynamic Determinants of Left Ventricular Hypertrophy. Hypertension, 2001, 38, 13-18.	2.7	109
50	Gender Differences in Left Ventricular Structure and Function During Antihypertensive Treatment. Hypertension, 2008, 51, 1109-1114.	2.7	109
51	Echocardiographic Left Ventricular Mass and Electrolyte Intake Predict Arterial Hypertension. Annals of Internal Medicine, 1991, 114, 202-209.	3.9	100
52	Antiâ€remodelling effect of canrenone in patients with mild chronic heart failure (AREA INâ€CHF study): final results. European Journal of Heart Failure, 2009, 11, 68-76.	7.1	99
53	Cardiovascular and Metabolic Predictors of Progression of Prehypertension Into Hypertension. Hypertension, 2009, 54, 974-980.	2.7	99
54	Gender differences in left ventricular anatomy, blood viscosity and volume regulatory hormones in normal adults. American Journal of Cardiology, 1991, 68, 1704-1708.	1.6	97

#	Article	IF	CITATIONS
55	Left ventricular concentric geometry is associated with impaired relaxation in hypertension: the HyperGEN study. European Heart Journal, 2005, 26, 1039-1045.	2.2	97
56	Relation of Left Ventricular Midwall Function to Cardiovascular Risk Factors and Arterial Structure and Function. Hypertension, 1998, 31, 929-936.	2.7	95
57	Does Information on Systolic and Diastolic Function Improve Prediction of a Cardiovascular Event by Left Ventricular Hypertrophy in Arterial Hypertension?. Hypertension, 2010, 56, 99-104.	2.7	93
58	Prevention and treatment of implanted central venous catheter (CVC) - related sepsis: A report after six years of home parenteral nutrition (HPN). Clinical Nutrition, 2002, 21, 207-211.	5.0	92
59	Relationship between left ventricular geometry and left atrial size and function in patients with systemic hypertension. Journal of Hypertension, 2004, 22, 1589-1596.	0.5	91
60	Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. Journal of Hypertension, 2005, 23, 2063-2070.	0.5	89
61	Four-Group Classification of Left Ventricular Hypertrophy Based on Ventricular Concentricity and Dilatation Identifies a Low-Risk Subset of Eccentric Hypertrophy in Hypertensive Patients. Circulation: Cardiovascular Imaging, 2014, 7, 422-429.	2.6	87
62	Left Ventricular Hypertrophy Regression During Antihypertensive Treatment in an Outpatient Clinic (the Campania Salute Network). Journal of the American Heart Association, 2017, 6, .	3.7	87
63	Cardiovascular risk in relation to a new classification of hypertensive left ventricular geometric abnormalities. Journal of Hypertension, 2015, 33, 745-754.	0.5	86
64	Left ventricular chamber and wall mechanics in the presence of concentric geometry. Journal of Hypertension, 1999, 17, 1001-1006.	0.5	85
65	Cardiac Markers of Pre-Clinical Disease in Adolescents With the Metabolic Syndrome. Journal of the American College of Cardiology, 2008, 52, 932-938.	2.8	84
66	Ambulatory Blood Pressure and M;etabolic Abnormalities in Hypertensive Subjects With Inappropriately High Left Ventricular Mass. Hypertension, 1999, 34, 1032-1040.	2.7	83
67	Prevalence and Prognostic Significance of Wall-Motion Abnormalities in Adults Without Clinically Recognized Cardiovascular Disease. Circulation, 2007, 116, 143-150.	1.6	82
68	Right atrial size and function in patients with pulmonary hypertension associated with disorders of respiratory system or hypoxemia. European Journal of Echocardiography, 2007, 8, 322-331.	2.3	81
69	Left ventricular filling pattern in uncomplicated obesity. American Journal of Cardiology, 1996, 77, 509-514.	1.6	80
70	Sex differences in obesity-related changes in left ventricular morphology: the Strong Heart Study. Journal of Hypertension, 2011, 29, 1431-1438.	0.5	80
71	A meta-analysis of the impact of pre-existing and new-onset atrial fibrillation on clinical outcomes in patients undergoing transcatheter aortic valve implantation. EuroIntervention, 2016, 12, e1047-e1056.	3.2	80
72	Prognostic implications of the compensatory nature of left ventricular mass in arterial hypertension. Journal of Hypertension, 2001, 19, 119-125.	0.5	75

#	Article	IF	CITATIONS
73	Left Atrial Systolic Force and Cardiovascular OutcomeThe Strong Heart Study. American Journal of Hypertension, 2005, 18, 1570-1576.	2.0	75
74	Relation of age to left ventricular function in clinically normal adults. American Journal of Cardiology, 1998, 82, 621-626.	1.6	74
75	Insufficient Control of Blood Pressure and Incident Diabetes. Diabetes Care, 2009, 32, 845-850.	8.6	74
76	Reduced hemodynamic load and cardiac hypotrophy in patients with anorexia nervosa. American Journal of Clinical Nutrition, 2003, 77, 308-312.	4.7	73
77	Lack of Reduction of Left Ventricular Mass in Treated Hypertension: The Strong Heart Study. Journal of the American Heart Association, 2013, 2, e000144.	3.7	72
78	Association of Blood Pressure With Blood Viscosity in American Indians. Hypertension, 2005, 45, 625-630.	2.7	71
79	Reliability and limitations of echocardiographic measurement of left ventricular mass for risk stratification and follow-up in single patients. Journal of Hypertension, 1999, 17, 1955-1963.	0.5	69
80	Executive Summary: Heart Disease and Stroke Statistics—2011 Update. Circulation, 2011, 123, 459-463.	1.6	69
81	Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: The LIFE Study. American Heart Journal, 2001, 141, 784-791.	2.7	68
82	Is High Pulse Pressure a Marker of Preclinical Cardiovascular Disease?. Hypertension, 2005, 45, 575-579.	2.7	68
83	Left ventricular hypertrophy offsets the sex difference in cardiovascular risk (the Campania Salute) Tj ETQq1 1 ().784314 r 1.7	gBT_/Overlock
84	Reduced Systolic Myocardial Function in Children with Chronic Renal Insufficiency. Journal of the American Society of Nephrology: JASN, 2007, 18, 593-598.	6.1	63
85	Hypertensive target organ damage predicts incident diabetes mellitus. European Heart Journal, 2013, 34, 3419-3426.	2.2	60
86	Relations of diastolic left ventricular filling to systolic chamber and myocardial contractility in hypertensive patients with left ventricular hypertrophy (the PRESERVE study). American Journal of Cardiology, 1999, 84, 558-562.	1.6	59
87	Development of Left Ventricular Hypertrophy in Treated Hypertensive Outpatients. Hypertension, 2017, 69, 136-142.	2.7	59
88	Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients. European Heart Journal Cardiovascular Imaging, 2017, 18, 945-960.	1.2	59
89	Appropriate or inappropriate left ventricular mass in the presence or absence of prognostically adverse left ventricular hypertrophy. Journal of Hypertension, 2001, 19, 1113-1119.	0.5	58
90	Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. Diabetes, Obesity and Metabolism, 2000, 2, 355-362.	4.4	56

#	Article	IF	CITATIONS
91	Gender differences in left ventricular chamber and midwall systolic function in normotensive and hypertensive adults. Journal of Hypertension, 2003, 21, 1415-1423.	0.5	55
92	Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2006, 37, 81-88.	2.4	55
93	Higher pulse pressure and risk for cardiovascular events in patients with essential hypertension: The Campania Salute Network. European Journal of Preventive Cardiology, 2018, 25, 235-243.	1.8	55
94	Depressed myocardial energetic efficiency is associated with increased cardiovascular risk in hypertensive left ventricular hypertrophy. Journal of Hypertension, 2016, 34, 1846-1853.	0.5	54
95	Coronary flow reserve in hypertensive patients with appropriate or inappropriate left ventricular mass. Journal of Hypertension, 2003, 21, 2183-2188.	0.5	53
96	Chronic kidney disease elicits excessive increase in left ventricular mass growth in patients at increased risk for cardiovascular events. Journal of Hypertension, 2011, 29, 565-573.	0.5	53
97	Nebivolol improves coronary flow reserve in hypertensive patients without coronary heart disease. Journal of Hypertension, 2004, 22, 2201-2208.	0.5	51
98	Left ventricular geometry in obesity: Is it what we expect?. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 905-912.	2.6	51
99	Different Normalizations for Body Size and Population Attributable Risk of Left Ventricular Hypertrophy: The MAVI Study. American Journal of Hypertension, 2005, 18, 1288-1293.	2.0	50
100	Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: The Strong Heart Study. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 98-104.	2.6	50
101	Hypertension and Cardiac Arrhythmias: Executive Summary of a Consensus Document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de EstimulaciÃ ³ n CardÃaca y ElectrofisiologÃa (SOLEACE). European Heart Journal - Cardiovascular	3.0	50
102	Left Ventricular Filling in Arterial Hypertension. Hypertension, 1997, 29, 544-550.	2.7	50
103	Assessment of cardiac autonomic control by heart period variability in patients with early-onset familial obesity. European Journal of Clinical Investigation, 1995, 25, 826-832.	3.4	49
104	Severe obstructive sleep apnea elicits concentric left ventricular geometry. Journal of Hypertension, 2010, 28, 1074-1082.	0.5	49
105	Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. Journal of Human Hypertension, 2007, 21, 625-632.	2.2	48
106	Change in cardiovascular risk profile by echocardiography in low- or medium-risk hypertension. Journal of Hypertension, 2002, 20, 1519-1525.	0.5	47
107	Impaired Inotropic Response in Type 2 Diabetes Mellitus: A Strain Rate Imaging Study. American Journal of Hypertension, 2007, 20, 548-555.	2.0	47
108	Usefulness of Subnormal Midwall Fractional Shortening in Predicting Left Ventricular Exercise Dysfunction in Asymptomatic Patients With Systemic Hypertension. American Journal of Cardiology, 1997, 79, 1070-1074.	1.6	46

#	Article	IF	CITATIONS
109	Hemodynamic hypertrophied left ventricular patterns in systemic hypertension. American Journal of Cardiology, 1987, 60, 1317-1321.	1.6	45
110	Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham Risk Score in individuals with dyslipidemia. Journal of Hypertension, 2010, 28, 1482-1487.	0.5	45
111	Influence of Left Ventricular Stroke Volume on Incident Heart Failure in a Population With Preserved Ejection Fraction (from the Strong Heart Study). American Journal of Cardiology, 2017, 119, 1047-1052.	1.6	45
112	Inappropriate left ventricular mass in normotensive and hypertensive patients. American Journal of Cardiology, 2001, 87, 361-363.	1.6	44
113	Left Ventricular Geometry and Hypotension in End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2003, 14, 2421-2427.	6.1	44
114	Myocardial mechano-energetic efficiency in hypertensive adults. Journal of Hypertension, 2009, 27, 650-655.	0.5	44
115	Diagnostic performance of multi-organ ultrasound with pocket-sized device in the management of acute dyspnea. Cardiovascular Ultrasound, 2017, 15, 16.	1.6	44
116	Body composition and fat distribution influence systemic hemodynamics in the absence of obesity: the HyperGEN Study. American Journal of Clinical Nutrition, 2005, 81, 757-761.	4.7	43
117	Body Build and Risk of Cardiovascular Events in Hypertension and Left Ventricular Hypertrophy. Circulation, 2005, 111, 1924-1931.	1.6	43
118	Association of suboptimal blood pressure control with body size and metabolic abnormalities. Journal of Hypertension, 2007, 25, 2296-2300.	0.5	43
119	Myocardial mechano-energetic efficiency and insulin resistance in non-diabetic members of the Strong Heart Study cohort. Cardiovascular Diabetology, 2019, 18, 56.	6.8	43
120	Cardiac Geometry and Function in Diabetic or Prediabetic Adolescents and Young Adults. Diabetes Care, 2011, 34, 2300-2305.	8.6	42
121	Influence of Obesity on Left Ventricular Midwall Mechanics in Arterial Hypertension. Hypertension, 1996, 28, 276-283.	2.7	41
122	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Heart Failure, 2022, 24, 143-168.	7.1	41
123	Left atrial dilatation: A target organ damage in young to middle-age hypertensive patients. The Campania Salute Network. International Journal of Cardiology, 2018, 265, 229-233.	1.7	40
124	Fibrinogen and Preclinical Echocardiographic Target Organ Damage. Hypertension, 2001, 38, 1068-1074.	2.7	39
125	Association of inappropriate left ventricular mass with systolic and diastolic dysfunctionThe HyperGEN study. American Journal of Hypertension, 2004, 17, 828-833.	2.0	39
126	Prognostic Value of Serial Electrocardiographic Voltage and Repolarization Changes in Essential Hypertension: The HEART Survey Study. American Journal of Hypertension, 2007, 20, 997-1004.	2.0	39

#	Article	IF	CITATIONS
127	Noninvasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients. Journal of Hypertension, 2017, 35, 1727-1741.	0.5	39
128	Antihypertensive and cardiovascular effects of nitrendipine: A controlled study vs. placebo. Clinical Pharmacology and Therapeutics, 1985, 38, 434-438.	4.7	38
129	Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension. American Journal of Cardiology, 1999, 83, 1196-1200.	1.6	38
130	Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: The strong heart study. American Heart Journal, 2003, 145, 467-474.	2.7	37
131	Concentric or Eccentric Hypertrophy: How Clinically Relevant Is the Difference?. Hypertension, 2004, 43, 714-715.	2.7	37
132	Cardiovascular ultrasound exploration contributes to predict incident atrial fibrillation in arterial hypertension: The Campania Salute Network. International Journal of Cardiology, 2015, 199, 290-295.	1.7	37
133	Left Ventricular Mass as a Measure of Preclinical Hypertensive Disease. American Journal of Hypertension, 1992, 5, 175S-181S.	2.0	35
134	Echocardiography in arterial hypertension. Journal of Hypertension, 1994, 12, 1129???1136.	0.5	35
135	Relation of left ventricular longitudinal and circumferential shortening to ejection fraction in the presence or in the absence of mild hypertension. Journal of Hypertension, 1997, 15, 1011-1017.	0.5	35
136	Obesity and hypertensive heart disease: focus on body composition and sex differences. Diabetology and Metabolic Syndrome, 2016, 8, 79.	2.7	35
137	Validation of Left Atrial Volume Estimation by Left Atrial Diameter from the Parasternal Long-Axis View. Journal of the American Society of Echocardiography, 2017, 30, 262-269.	2.8	35
138	Analysis of Circumferential and Longitudinal Left Ventricular Systolic Function in Patients With Non-Ischemic Chronic Heart Failure and Preserved Ejection Fraction (from the CARRY-IN-HFpEF Study). American Journal of Cardiology, 2012, 109, 383-389.	1.6	34
139	Serum uric acid does not predict incident metabolic syndrome in a population with high prevalence of obesity. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 1360-1364.	2.6	34
140	Estimate of white-coat effect and arterial stiffness. Journal of Hypertension, 2007, 25, 827-831.	0.5	33
141	Impact of pulse pressure on left ventricular global longitudinal strain in normotensive and newly diagnosed, untreated hypertensive patients. Journal of Hypertension, 2016, 34, 1201-1207.	0.5	33
142	Relations of Left Ventricular Geometry and Function to Body Composition in Children With High Casual Blood Pressure. Hypertension, 1997, 30, 377-382.	2.7	33
143	Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study. American Journal of Medicine, 2002, 112, 710-715.	1.5	32
144	Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin. Journal of Thrombosis and Haemostasis, 2007, 5, 2197-2203.	3.8	32

#	Article	IF	CITATIONS
145	Nonsymmetric Myocardial Contribution to Supranormal Right Ventricular Function in the Athlete's Heart: Combined Assessment by Speckle Tracking and Real Time Threeâ€Dimensional Echocardiography. Echocardiography, 2014, 31, 996-1004.	0.9	32
146	Differential effect of obesity on prevalence of cardiac and carotid target organ damage in hypertension (the Campania Salute Network). International Journal of Cardiology, 2017, 244, 260-264.	1.7	32
147	Rationale of Echocardiographic Assessment of Left Ventricular Wall Stress and Midwall Mechanics in Hypertensive Heart Disease. European Journal of Echocardiography, 2002, 3, 192-198.	2.3	32
148	Diastolic Dysfunction in Arterial Hypertension. Journal of Clinical Hypertension, 2001, 3, 22-27.	2.0	31
149	Relation of hemodynamics and risk factors to ventricular–vascular interactions in the elderly: the Cardiovascular Health Study. Journal of Hypertension, 2001, 19, 1893-1903.	0.5	31
150	Coronary Vasodilator Capacity and Hypertension-Induced Increase in Left Ventricular Mass. Hypertension, 2003, 41, 224-229.	2.7	31
151	Identification of a novel 5–base pair deletion in calcineurin B (PPP3R1) promoter region and its association with left ventricular hypertrophy. American Heart Journal, 2005, 150, 845-851.	2.7	31
152	Tight Versus Standard Blood Pressure Control in Patients With Hypertension With and Without Cardiovascular Disease. Hypertension, 2014, 63, 475-482.	2.7	31
153	Excessive increase in left ventricular mass identifies hypertensive subjects with clustered geometric and functional abnormalities. Journal of Hypertension, 2007, 25, 1073-1078.	0.5	30
154	Relative fat-free mass deficiency and left ventricular adaptation to obesity: The Strong Heart Study. International Journal of Cardiology, 2013, 168, 729-733.	1.7	30
155	Site-dependency of the E/e' ratio in predicting invasive left ventricular filling pressure in patients with suspected or ascertained coronary artery disease. European Heart Journal Cardiovascular Imaging, 2013, 14, 555-561.	1.2	30
156	Cardiovascular Characteristics in Subjects With Increasing Levels of Abnormal Glucose Regulation. Diabetes Care, 2013, 36, 992-997.	8.6	30
157	Left Ventricular Hypertrophy and Hypertension. Clinical and Experimental Hypertension, 1993, 15, 1025-1032.	1.3	29
158	Sibutramine: Balancing weight loss benefit and possible cardiovascular risk. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 337-341.	2.6	29
159	Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 634-640.	2.6	29
160	Target organ damage and incident type 2 diabetes mellitus: the Strong Heart Study. Cardiovascular Diabetology, 2017, 16, 64.	6.8	29
161	Depressed Myocardial Energetic Efficiency Increases Risk of Incident Heart Failure: The Strong Heart Study. Journal of Clinical Medicine, 2019, 8, 1044.	2.4	29
162	Nebivolol induces parallel improvement of left ventricular filling pressure and coronary flow reserve in uncomplicated arterial hypertension. Journal of Hypertension, 2009, 27, 2108-2115.	0.5	28

#	Article	IF	CITATIONS
163	Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 415-423.	2.8	28
164	Echocardiography in Arterial Hypertension. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 159-166.	2.2	28
165	Aortic Root Dilatation Is Associated With Incident Cardiovascular Events in a Population of Treated Hypertensive Patients: The Campania Salute Network. American Journal of Hypertension, 2018, 31, 1317-1323.	2.0	28
166	Impact of the 2017 Blood Pressure Guidelines by the American Academy of Pediatrics in overweight/obese youth. Journal of Hypertension, 2019, 37, 732-738.	0.5	28
167	Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study). Blood Pressure, 2014, 23, 206-212.	1.5	27
168	Aortic root dimension and arterial stiffness in arterial hypertension. Journal of Hypertension, 2016, 34, 1109-1114.	0.5	27
169	Elevated blood pressure, cardiometabolic risk and target organ damage in youth with overweight and obesity. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1840-1847.	2.6	27
170	Reduction of development of left ventricular hypertrophy in salt-loaded Dahl salt-sensitive rats by angiotensin II receptor inhibition. American Journal of Hypertension, 1996, 9, 216-222.	2.0	26
171	Independent Association of Coronary Flow Reserve with Left Ventricular Relaxation and Filling Pressure in Arterial Hypertension. American Journal of Hypertension, 2008, 21, 1040-1046.	2.0	26
172	Arterial Stiffness Is Associated With Carotid Atherosclerosis in Hypertensive Patients (The Campania) Tj ETQq0 () 0 rgBT /0 2:0	Overlock 10 Tf
173	Impact of overweight and obesity on cardiac benefit of antihypertensive treatment. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 122-129.	2.6	26
174	Allometric Normalization of Cardiac Measures: Producing Better, but Imperfect, Accuracy. Journal of the American Society of Echocardiography, 2014, 27, 1275-1278.	2.8	26
175	Usefulness of Subclinical Left Ventricular Midwall Dysfunction to Predict Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2014, 113, 1409-1414.	1.6	26
176	In vivo left ventricular anatomy in rats with two-kidney, one clip and one-kidney, one clip renovascular hypertension. Journal of Hypertension, 1992, 10, 5.	0.5	25
177	Relation of insulin to left ventricular geometry and function in African American and white hypertensive adults: the HyperGEN study. American Journal of Hypertension, 2002, 15, 1029-1035.	2.0	25
178	Left Atrial Systolic Force and Cardiac Markers of Preclinical Disease in Hypertensive PatientsThe Hypertension Genetic Epidemiology Network (HyperGEN) Study. American Journal of Hypertension, 2005, 18, 899-905.	2.0	25
179	Left ventricular mass and incident hypertension in individuals with initial optimal blood pressure: the Strong Heart Study. Journal of Hypertension, 2008, 26, 1868-1874.	0.5	25
180	Initial left-ventricular mass predicts probability of uncontrolled blood pressure in arterial hypertension. Journal of Hypertension, 2011, 29, 803-808.	0.5	25

#	Article	IF	CITATIONS
181	Mitral Annular Calcification and Incident Ischemic Stroke in Treated Hypertensive Patients: The LIFE study American Journal of Hypertension, 2013, 26, 567-573.	2.0	25
182	Relations of pulse pressure and other components of blood pressure to preclinical echocardiographic abnormalities. Journal of Hypertension, 2002, 20, 531-537.	0.5	24
183	Association of inappropriate left ventricular mass with systolic and diastolic dysfunction: the HyperGEN study. American Journal of Hypertension, 2004, 17, 828-833.	2.0	24
184	Increased left ventricular mass in pre-liver transplantation cirrhotic patients. Journal of Cardiovascular Medicine, 2008, 9, 142-146.	1.5	24
185	Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. Journal of Hypertension, 2009, 27, 567-574.	0.5	24
186	Classes of antihypertensive medications and blood pressure control in relation to metabolic risk factors. Journal of Hypertension, 2012, 30, 188-193.	0.5	24
187	Hemodynamic Correlates of Abnormal Aortic Root Dimension in an Adult Population: The Strong Heart Study. Journal of the American Heart Association, 2015, 4, e002309.	3.7	24
188	Assessment of left ventricular function by meridional and circumferential endsystolic stress/minor-axis shortening relations in dilated cardiomyopathy. American Journal of Cardiology, 1996, 78, 544-549.	1.6	23
189	Inappropriate left ventricular mass: reliability and limitations of echocardiographic measurement for risk stratification and follow-up in single patients. Journal of Hypertension, 2006, 24, 2293-2298.	0.5	23
190	Coronary Flow Reserve in Hypertensive Patients With Hypercholesterolemia and Without Coronary Heart Disease. American Journal of Hypertension, 2007, 20, 177-183.	2.0	23
191	Markers of Inflammation, Metabolic Risk Factors, and Incident Heart Failure in American Indians: The Strong Heart Study. Journal of Clinical Hypertension, 2012, 14, 13-19.	2.0	23
192	Relationship between plasma plasminogen activator inhibitor-1 and hypertension in American Indians. Journal of Hypertension, 2017, 35, 1787-1793.	0.5	23
193	Left Ventricular Hypertrophy Associated with Hypertension and Its Relevance as a Risk Factor for Complications. Journal of Cardiovascular Pharmacology, 1993, 21, S38-S44.	1.9	22
194	Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects. Nutrition, Metabolism and Cardiovascular Diseases, 2005, 15, 24-30.	2.6	22
195	Development of new atherosclerotic plaque in hypertensive patients. Journal of Hypertension, 2015, 33, 2471-2476.	0.5	22
196	State of the heart in the metabolic syndrome. Nutrition, Metabolism and Cardiovascular Diseases, 2005, 15, 239-241.	2.6	21
197	Morbid Obesity and Left Ventricular Geometry. Hypertension, 2007, 49, 7-9.	2.7	21
198	Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. Journal of Hypertension, 2007, 25, 1079-1085.	0.5	21

#	Article	IF	CITATIONS
199	Evaluation of Systolic Properties in Hypertensive Patients With Different Degrees of Diastolic Dysfunction and Normal Ejection Fraction. American Journal of Hypertension, 2009, 22, 437-443.	2.0	21
200	Hemoglobin A1c, Fasting Glucose, and Cardiovascular Risk in a Population With High Prevalence of Diabetes. Diabetes Care, 2011, 34, 1952-1958.	8.6	21
201	Cardiometabolic risk in overweight subjects with or without relative fat-free mass deficiency: The Strong Heart Study. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 271-276.	2.6	21
202	Speculation is not evidence: antihypertensive therapy and COVID-19. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 133-134.	3.0	21
203	Management of patients with combined arterial hypertension and aortic valve stenosis: a consensus document from the Council on Hypertension and Council on Valvular Heart Disease of the European Society of Cardiology, the European Association of Cardiovascular Imaging (EACVI), and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal -	3.0	21
204	Ambulatory Blood Pressure Monitoring in Offspring of Hypertensive Patients Relation to Left Ventricular Structure and Function. American Journal of Hypertension, 1993, 6, 114-120.	2.0	20
205	Myocardial function and geometry in hypertensive subjects with low levels of afterload. American Heart Journal, 2002, 143, 546-551.	2.7	20
206	Mitral E Wave Deceleration Time to Peak E Velocity Ratio and Cardiovascular Outcome in Hypertensive Patients During Antihypertensive Treatment (from the LIFE Echo-Substudy). American Journal of Cardiology, 2009, 104, 1098-1104.	1.6	20
207	Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: The AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 783-791.	2.6	20
208	Are Observational Studies More Informative Than Randomized Controlled Trials in Hypertension?. Hypertension, 2013, 62, 463-469.	2.7	20
209	Cardiometabolic Phenotype in Children with Obesity. Journal of Pediatrics, 2014, 165, 1184-1189.	1.8	20
210	Impact of stroke volume on cardiovascular risk during progression of aortic valve stenosis. Heart, 2017, 103, 1443-1448.	2.9	20
211	Assessment of left atrial size in addition to focused cardiopulmonary ultrasound improves diagnostic accuracy of acute heart failure in the Emergency Department. Echocardiography, 2018, 35, 785-791.	0.9	20
212	Three-dimensional echocardiographic ventricular mass/end-diastolic volume ratio in native hypertensive patients. Journal of Hypertension, 2018, 36, 1697-1704.	0.5	20
213	COVID-19: Timing is Important. European Journal of Internal Medicine, 2020, 77, 134-135.	2.2	20
214	Clinical impact of various geometric models for calculation of echocardiographic left ventricular mass. Journal of Hypertension, 1998, 16, 1207-1214.	0.5	19
215	Inappropriately high left-ventricular mass in asymptomatic mild-moderate aortic stenosis. Journal of Hypertension, 2012, 30, 421-428.	0.5	19
216	Does cardiovascular phenotype explain the association between diabetes and incident heart failure? The Strong Heart Study. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 285-291.	2.6	19

#	Article	IF	CITATIONS
217	Insulin Resistance, Incident Cardiovascular Diseases, and Decreased Kidney Function Among Nondiabetic American Indians. Diabetes Care, 2013, 36, 3195-3200.	8.6	19
218	Depressed Atrial Function in Diastolic Dysfunction: A Speckle Tracking Imaging Study. Echocardiography, 2013, 30, 309-316.	0.9	19
219	Relation of Age to Left Ventricular Function and Systemic Hemodynamics in Uncomplicated Mild Hypertension. Hypertension, 2001, 37, 1404-1409.	2.7	18
220	Relation of insulin resistance to markers of preclinical cardiovascular disease: the Strong Heart Study. Nutrition, Metabolism and Cardiovascular Diseases, 2003, 13, 140-147.	2.6	18
221	Compensatory or inappropriate left ventricular mass in different models of left ventricular pressure overload: comparison between patients with aortic stenosis and arterial hypertension. Journal of Hypertension, 2009, 27, 642-649.	0.5	18
222	Inappropriately high left ventricular mass in patients with type 2 diabetes mellitus and no overt cardiac disease. The DYDA study. Journal of Hypertension, 2011, 29, 1994-2003.	0.5	17
223	Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of) Tj ETQq1 1 0. Cardiovascular Medicine, 2007, 8, 683-691.	784314 rgł 1.5	3T /Overlock 16
224	Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of Hypertension, 2008, 26, 1472-1476.	0.5	16
225	Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 1101-1106.	2.6	16
226	Determinants of decline of renal function in treated hypertensive patients: the Campania Salute Network. Nephrology Dialysis Transplantation, 2018, 33, 435-440.	0.7	16
227	Weight loss facilitates reduction of left ventricular mass in obese hypertensive patients: The Campania Salute Network. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 185-190.	2.6	16
228	The American Academy of Pediatrics hypertension guidelines identify obese youth at high cardiovascular risk among individuals non-hypertensive by the European Society of Hypertension guidelines. European Journal of Preventive Cardiology, 2020, 27, 8-15.	1.8	16
229	Should all patients with hypertension have echocardiography?. Journal of Human Hypertension, 2000, 14, 417-421.	2.2	15
230	QTLs of factors of the metabolic syndrome and echocardiographic phenotypes: the hypertension genetic epidemiology network study. BMC Medical Genetics, 2008, 9, 103.	2.1	15
231	Parallel improvement of left ventricular geometry and filling pressure after transcatheter aortic valve implantation in high risk aortic stenosis: comparison with major prosthetic surgery by standard echo Doppler evaluation. Cardiovascular Ultrasound, 2013, 11, 18.	1.6	15
232	Inappropriate left ventricular mass independently predicts cardiovascular mortality in patients with type 2 diabetes. International Journal of Cardiology, 2013, 168, 4953-4956.	1.7	15
233	Assessment of the interaction of heritability of volume load and left ventricular mass: the HyperGEN offspring study. Journal of Hypertension, 2007, 25, 1397-1402.	0.5	14
234	Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study. Blood Pressure, 2017, 26, 150-155.	1.5	14

#	Article	IF	CITATIONS
235	Echocardiography in Lowâ€Risk Hypertensive Patients. Journal of the American Heart Association, 2019, 8, e013497.	3.7	14
236	Left atrial size and force in patients with systolic chronic heart failure: Comparison with healthy controls and different cardiac diseases. Experimental and Clinical Cardiology, 2010, 15, e45-51.	1.3	14
237	Low mechanoâ€energetic efficiency is associated with future left ventricular systolic dysfunction in hypertensives. ESC Heart Failure, 2022, 9, 2291-2300.	3.1	14
238	Efficacy of very low dose perindopril 2 mg/indapamide 0.625 mg combination on left ventricular hypertrophy in hypertensive patients: the P.I.C.X.E.L. study rationale and design. Journal of Human Hypertension, 2002, 16, 653-659.	2.2	13
239	The Metabolic Syndrome in American Indians: The Strong Heart Study. Journal of the Cardiometabolic Syndrome, 2007, 2, 283-287.	1.7	13
240	Factor relationships of metabolic syndrome and echocardiographic phenotypes in the HyperGEN study. Journal of Hypertension, 2008, 26, 1360-1366.	0.5	13
241	Method Errors or Unexplained Biological Information?. Hypertension, 2010, 56, e177-8.	2.7	13
242	Echocardiography in clinical practice: the burden of arterial hypertension. A multicenter Italian survey. Journal of Human Hypertension, 2010, 24, 395-402.	2.2	13
243	Diastolic bicycle stress echocardiography: Normal reference values in a middle age population. International Journal of Cardiology, 2015, 191, 181-183.	1.7	13
244	Preliminary evaluation of the prevalence of sarcopenia in obese patients from Southern Italy. Nutrition, 2015, 31, 79-83.	2.4	13
245	Identification of phenotypes at risk of transition from diastolic hypertension to isolated systolic hypertension. Journal of Human Hypertension, 2016, 30, 392-396.	2.2	13
246	Normal Left Ventricle. American Journal of Noninvasive Cardiology, 1988, 2, 217-223.	0.1	12
247	Echocardiographic Assessment of Left Ventricular Hypertrophy in Rats Using a Simplified Approach. American Journal of Hypertension, 1994, 7, 555-558.	2.0	12
248	Myocardial Texture in Hypertrophic Cardiomyopathy. Journal of the American Society of Echocardiography, 2007, 20, 1253-1259.	2.8	12
249	Left Atrial Systolic Force and Outcome in Asymptomatic Mild to Moderate Aortic Stenosis. Echocardiography, 2012, 29, 1038-1044.	0.9	12
250	Atrial Dilatation Development in Hypertensive Treated Patients: The Campania-Salute Network. American Journal of Hypertension, 2016, 29, 1077-1084.	2.0	12
251	Left Ventricular Mass in Hypertrophic Cardiomyopathy Assessed by 2D-Echocardiography: Validation with Magnetic Resonance Imaging. Journal of Cardiovascular Translational Research, 2020, 13, 238-244.	2.4	12
252	Determinants of aortic root dilatation over time in patients with essential hypertension: The Campania Salute Network. European Journal of Preventive Cardiology, 2021, 28, 1508-1514.	1.8	12

#	Article	IF	CITATIONS
253	Influence of cardiovascular risk factors on relation between angiotensin converting enzyme-gene polymorphism and blood pressure in arterial hypertension. Journal of Hypertension, 1998, 16, 985-991.	0.5	11
254	Acute Hyperglycemia Does Not Affect the Reactivity of Coronary Microcirculation in Humans. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3871-3876.	3.6	11
255	Association of Hemoglobin Delivery With Left Ventricular Structure and Function in Hypertensive Patients. Hypertension, 2006, 47, 868-873.	2.7	11
256	Nutraceuticals for Treatment of High Blood Pressure Values in Patients with Metabolic Syndrome. High Blood Pressure and Cardiovascular Prevention, 2009, 16, 177-182.	2.2	11
257	Persistence and adherence to antihypertensive treatment in relation to initial prescription. Journal of Hypertension, 2012, 30, 1225-1232.	0.5	11
258	Effect of bariatric surgery on left ventricular geometry and function in severe obesity. Obesity Research and Clinical Practice, 2012, 6, e189-e196.	1.8	11
259	STEMI and NSTEMI: A mono versus a multivessel disease?. International Journal of Cardiology, 2013, 168, 2905-2906.	1.7	11
260	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Preventive Cardiology, 2022, 29, 275-300.	1.8	11
261	Association of Myocardial Energetic Efficiency with Circumferential and Longitudinal Left Ventricular Myocardial Function in Subjects with Increased Body Mass Index (the FATCOR Study). Journal of Clinical Medicine, 2021, 10, 1581.	2.4	11
262	Guidelines for arterial hypertension. Journal of Hypertension, 1999, 17, 735-736.	0.5	10
263	Arterial Hypertension and Cardiac Damage. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 141-170.	2.2	10
264	Left Atrial Systolic Force in Asymptomatic Aortic Stenosis. Echocardiography, 2011, 28, 968-977.	0.9	10
265	Severity of Coronary Atherosclerosis and Risk of Diabetes Mellitus. Journal of Clinical Medicine, 2019, 8, 1069.	2.4	10
266	Anterior vs lateral symmetric interstitial syndrome in the diagnosis of acute heart failure. International Journal of Cardiology, 2019, 280, 130-132.	1.7	10
267	The Global Ambulatory Blood Pressure Monitoring (ABPM) in Heart Failure with Preserved Ejection Fraction (HFpEF) Registry. Rationale, design and objectives. Journal of Human Hypertension, 2020, 35, 1029-1037.	2.2	10
268	Incidence of cerebral venous thrombosis and COVID-19 vaccination: possible causal effect or just chance?. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e77-e78.	3.0	10
269	Effects of Nicardipine on Left Ventricular Hemodynamic Patterns in Systemic Hypertension. American Journal of Hypertension, 1989, 2, 139-145.	2.0	9
270	The Effects of Nicardipine on Sodium and Calcium Metabolism in Hypertensive Patients: A Chronic Study. Journal of Clinical Pharmacology, 1990, 30, 133-137.	2.0	9

#	Article	IF	CITATIONS
271	Inappropriate left ventricular mass and angiotensin converting enzyme gene polymorphism. Journal of Human Hypertension, 2001, 15, 811-813.	2.2	9
272	Left ventricular hypertrophy in hypertension as a predictor of coronary events: relation to geometry. Current Opinion in Nephrology and Hypertension, 2002, 11, 215-220.	2.0	9
273	Serial echocardiographic assessment of left ventricular mass. Journal of Hypertension, 2004, 22, 1813-1818.	0.5	9
274	Aortic Root Dimension and Hypertension: A Chicken-Egg Dilemma. American Journal of Hypertension, 2008, 21, 489-490.	2.0	9
275	Clinical impact of â€~in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of Hypertension, 2008, 26, 806-812.	0.5	9
276	Left Ventricular Diastolic Dysfunction in Type I Gaucher Disease: An Echo Doppler Study. Echocardiography, 2015, 32, 890-895.	0.9	9
277	Target Organ Damage and Target Systolic Blood Pressure in Clinical Practice: The Campania Salute Network. American Journal of Hypertension, 2018, 31, 658-664.	2.0	9
278	Impact of visit-to-visit blood pressure variability on hypertensive-mediated target organ damage and future cardiovascular events: the Campania salute network. Journal of Hypertension, 2021, 39, 1852-1858.	0.5	9
279	Carotid Atherosclerosis Predicts Blood Pressure Control in Patients With Hypertension: The Campania Salute Network Registry. Journal of the American Heart Association, 2022, 11, e022345.	3.7	9
280	Depth variation bias and interaction with gain setting in ultrasonic tissue characterization by integrated backscatter analysis. Journal of the American Society of Echocardiography, 2003, 16, 54-60.	2.8	8
281	Influence of fat-free mass on detection of appropriateness of left ventricular mass. Journal of Hypertension, 2003, 21, 1747-1752.	0.5	8
282	Left Ventricular Hypertrophy in Blacks and Whites. Hypertension, 2005, 46, 23-24.	2.7	8
283	Combined Circumferential and Longitudinal Left Ventricular Systolic Dysfunction in Patients with Asymptomatic Aortic Stenosis. Echocardiography, 2015, 32, 1064-1072.	0.9	8
284	Is increased uric acid a risk factor or a defensive response? TheÂCampania Salute Network. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 839-846.	2.6	8
285	Impact of estimated left atrial volume on prognosis in patients with asymptomatic mild to moderate aortic valve stenosis. International Journal of Cardiology, 2019, 297, 121-125.	1.7	8
286	Hypertension in Women: Should There be a Sex-specific Threshold?. European Cardiology Review, 2021, 16, e38.	2.2	8
287	Is inappropriate left ventricular mass related to neurohormonal factors and/or arterial changes in hypertension? a LIFE substudy. Journal of Human Hypertension, 2004, 18, 437-443.	2.2	7
288	Electrocardiographic and Echocardiographic Detection of Myocardial Infarction in Patients with Left-Ventricular HypertrophyThe LIFE Study. American Journal of Hypertension, 2007, 20, 771-776.	2.0	7

#	Article	IF	CITATIONS
289	Molecular Determinants of the Cardiometabolic Phenotype. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2010, 10, 109-123.	1.2	7
290	Sodium, Left Ventricular Mass, and Arterial Hypertension. Hypertension, 2011, 58, 349-351.	2.7	7
291	Prognostic impact of increased pulse pressure/stroke index in a registry of hypertensive patients: the Campania Salute Network. Blood Pressure, 2019, 28, 268-275.	1.5	7
292	Characteristics and Outcomes of Patients Presenting With Hypertensive Urgency in the Office Setting: The Campania Salute Network. American Journal of Hypertension, 2020, 33, 414-421.	2.0	7
293	Sustained High D-Dimer in Outpatients Who Have Recovered from Mild to Moderate Coronavirus Disease 2019 (COVID-19). Seminars in Thrombosis and Hemostasis, 2021, , .	2.7	7
294	Regression of LVH or Reduction of Left Ventricular Mass?. American Journal of Hypertension, 2008, 21, 365-366.	2.0	6
295	Left atrial systolic force: comparison between two methods for the noninvasive assessment of left atrial systolic function. Journal of Cardiovascular Medicine, 2008, 9, 601-607.	1.5	6
296	Early markers of right heart involvement in regular smokers by Pocket Size Imaging Device. Cardiovascular Ultrasound, 2015, 13, 33.	1.6	6
297	Prevalence and characteristics of true and apparent treatment resistant hypertension in the Campania Salute Network. International Journal of Cardiology, 2015, 184, 417-419.	1.7	6
298	Achievement of target SBP without attention to decrease in DBP can increase cardiovascular morbidity in treated arterial hypertension. Journal of Hypertension, 2019, 37, 1889-1897.	0.5	6
299	Finding the right time for anti-inflammatory therapy in COVID-19. International Journal of Infectious Diseases, 2020, 101, 247-248.	3.3	6
300	Predictors and prognostic role of low myocardial mechano-energetic efficiency in chronic inflammatory arthritis. Journal of Hypertension, 2021, 39, 53-61.	0.5	6
301	Imaging techniques for non-invasive assessment of coronary heart disease in hypertension: value of an integrated approach. Journal of Hypertension, 2001, 19, 679-682.	0.5	5
302	Fat is bad. Journal of Hypertension, 2004, 22, 35-37.	0.5	5
303	Inappropriate left ventricular mass in children and young adults with chronic renal insufficiency. Pediatric Nephrology, 2009, 24, 2015-2022.	1.7	5
304	Early changes of myocardial deformation properties in patients with dystrophia myotonica type 1: A three-dimensional Speckle Tracking echocardiographic study. International Journal of Cardiology, 2014, 176, 1094-1096.	1.7	5
305	Cardiac adaptation to hypertension in adult female Dahl salt-sensitive rats is dependent on ovarian function, but loss of ovarian function does not predict early maladaptation. Physiological Reports, 2018, 6, e13593.	1.7	5
306	Interstitial syndrome-lung ultrasound B lines: a potential marker for pulmonary metastases? A case series. Italian Journal of Medicine, 2018, 12, 223-226.	0.3	5

#	Article	IF	CITATIONS
307	Echocardiographic indexes of left ventricular contractility. Effect of load manipulation in arterial hypertension International Heart Journal, 1988, 29, 151-160.	0.6	4
308	High pulse pressure as a marker of preclinical cardiovascular disease. Future Cardiology, 2006, 2, 165-168.	1.2	4
309	Partial normalization of components of metabolic syndrome does not influence prevalent echocardiographic abnormalities: The HyperGEN study. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 38-45.	2.6	4
310	Does metabolic syndrome worsen systolic dysfunction in diabetes? The shortwave study. Acta Diabetologica, 2015, 52, 143-151.	2.5	4
311	CHA2DS2-VASc score and left atrial volume dilatation synergistically predict incident atrial fibrillation in hypertension: an observational study from the Campania Salute Network registry. Scientific Reports, 2019, 9, 7888.	3.3	4
312	Slow-release nifedipine versus placebo in the treatment of arterial hypertension. A double blind ergometric evaluation of cardiac workload International Heart Journal, 1985, 26, 219-225.	0.6	4
313	Relation of Age to Left Ventricular Structure, Function, and Systemic Hemodynamics in Normotensive and Hypertensive Employed Adults. The American Journal of Geriatric Cardiology, 1992, 1, 29-42.	0.6	4
314	Extracellular matrix and left ventricular mechanics in overload hypertrophy. Advances in Clinical Pathology: the Official Journal of Adriatic Society of Pathology, 2002, 6, 3-10.	0.1	4
315	Left Ventricular Mass as an Indicator of Hemodynamic Load in Hypertension. Journal of Cardiovascular Pharmacology, 1991, 17, S33.	1.9	3
316	Assessing Left Ventricular Performance. Hypertension, 2008, 51, 179-181.	2.7	3
317	Are We Underestimating Prehypertension?. Hypertension, 2019, 73, 541-542.	2.7	3
318	Relations of Left Ventricular Geometry and Function to Prognosis in Hypertension. Advances in Experimental Medicine and Biology, 1997, 432, 1-12.	1.6	3
319	Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension study. Journal of Hypertension, 2010, 28, 1134-1140.	0.5	3
320	Value of Combined Circumferential and Longitudinal Left Ventricular Systolic Dysfunction to Predict Adverse Outcome in Patients with Asymptomatic Aortic Stenosis. Journal of Heart Valve Disease, 2016, 25, 28-38.	0.5	3
321	A Role for Steroid Hormones in the Variability of Blood Pressure Determination. Journal of Hypertension, 1986, 4, 501-505.	0.5	2
322	Body fat distribution and whole blood viscosity in a sample of Italian men and women. American Journal of Cardiology, 1994, 74, 200-202.	1.6	2
323	The issue of body size between methods and substance. Journal of Hypertension, 2008, 26, 178-181.	0.5	2
324	Corrigendum to "Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: The Strong Heart Study―[Nutr Metab Cardiovasc Dis 19 (2009) 98–104]. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 520.	2.6	2

#	Article	IF	CITATIONS
325	Serial speckle tracking and successful post-STEMI percutaneous coronary intervention: incremental value versus visual wall motion analysis. Journal of Cardiovascular Medicine, 2010, 11, 768-771.	1.5	2
326	The difficult clinical management of the combination of hypertension with aortic stenosis. Journal of Hypertension, 2010, 28, 234-236.	0.5	2
327	Preclinical Systolic Dysfunction in Patients with Stage 3 Chronic Kidney Disease. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 59-64.	2.2	2
328	Left ventricular hypertrophy. Journal of Hypertension, 2011, 29, 1480-1482.	0.5	2
329	Cardiovascular risk in subjects with left ventricular concentric remodeling: Does meta-analysis help reconcile inconsistent findings?. Journal of Human Hypertension, 2011, 25, 575-577.	2.2	2
330	A challenging diagnosis of dyspnea: A case report of contralateral reexpansion pulmonary edema. Monaldi Archives for Chest Disease, 2018, 88, 900.	0.6	2
331	Erectile dysfunction and arterial hypertension: Still looking for a scapegoat. European Journal of Internal Medicine, 2020, 81, 22-23.	2.2	2
332	Second Consensus on Treatment of Patients Recently Diagnosed With Mild Hypertension and Low Cardiovascular Risk. Current Problems in Cardiology, 2020, 45, 100653.	2.4	2
333	Survey on arterial hypertension management: a report from the ESC Council for Cardiology Practice and the ESC Council on Hypertension. European Heart Journal Open, 2021, 1, .	2.3	2
334	Left ventricular mass and blood pressure during ergometric exercise in primary hypertension International Heart Journal, 1987, 28, 349-356.	0.6	2
335	Development of systolic dysfunction unrelated to myocardial infarction in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study. Exploration of Medicine, 0, , 160-172.	1.5	2
336	Noninvasive assessment of hemodynamic changes during therapy with nitrendipine in arterial hypertension International Heart Journal, 1987, 28, 73-84.	0.6	1
337	Echocardiographie Assessment of Arterial Impedance: Relation to Anatomic Left Ventricular Patterns in Systemic Hypertension. American Journal of Noninvasive Cardiology, 1988, 2, 232-237.	0.1	1
338	What Is Bright Is Not Always Gold. Hypertension, 2003, 41, e9-10; author reply e9-10.	2.7	1
339	Serial echocardiographic assessment of left ventricular mass. Journal of Hypertension, 2005, 23, 461-462.	0.5	1
340	Response to Letter Regarding Article, "Cardiac Remodeling in Obesity― Circulation: Cardiovascular Imaging, 2013, 6, e18.	2.6	1
341	Should Thiazide Diuretics be Given as First Line Antihypertensive Therapy or in Addition to Other Medications?. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 55-59.	2.2	1
342	Very low reporting rate of connective tissue diseases among coronavirus disease 2019 (Covid-19) patients and the renin-angiotensin system – An overlooked association?. European Journal of Internal Medicine, 2020, 80, 106-107.	2.2	1

#	ARTICLE	IF	CITATIONS
343	Quantitation of left ventricular mass and function: balancing evidence with dreams. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2002, 3, 562-70.	0.1	1
344	Dipyridamole or dobutamine in arterial hypertension: are sensitivity and specificity the sole keywords?. Journal of Hypertension, 2002, 20, 1287-1289.	0.5	0
345	Job-Related Anxiety and Carotid Atherosclerosis. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 99-105.	2.2	0
346	Benefits of Diuretic-Based Low-Cost Antihypertensive Therapy. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 73-78.	2.2	0
347	Câ€Reactive Protein, Fibrinogen, and Incident Heart Failure in the Strong Heart Study Population. Journal of Clinical Hypertension, 2013, 15, 299-299.	2.0	0
348	Obituary. Blood Pressure, 2017, 26, 191-191.	1.5	0
349	Uncommon case of pericardial effusion. Italian Journal of Medicine, 2017, 11, 331.	0.3	0
350	Light and shade of the pulse waveform analysis. Journal of Hypertension, 2018, 36, 765-767.	0.5	0
351	Reply. Journal of Hypertension, 2018, 36, 1946-1947.	0.5	0
352	Renal artery stenosis in a young female patient with severe hypertension - a case report. Italian Journal of Medicine, 2019, 13, 176-180.	0.3	0
353	Primum non nocere. Journal of Human Hypertension, 2020, 34, 547-550.	2.2	0
354	Maurizio Galderisi. In Memoriam. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 177-178.	2.2	0
355	Clinical value of diastolic dysfunciton in hypertension. Journal of Hypertension, 2002, 20, 2309-2310.	0.5	0
356	Follow-Up of the Hypertensive Patients with Cardiovascular Disease. , 2016, , 261-277.		0
357	A case of phenotypic Anderson-Fabry disease in a female patient. Gazzetta Medica Italiana Archivio Per Le Scienze Mediche, 2018, 177, .	0.1	0